Dynamic Technology Lab Private Ltd Takes Position in Afya Limited $AFYA

Dynamic Technology Lab Private Ltd purchased a new position in shares of Afya Limited (NASDAQ:AFYA) in the 2nd quarter, HoldingsChannel.com reports. The institutional investor purchased 21,869 shares of the company’s stock, valued at approximately $391,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Nuveen LLC acquired a new position in Afya in the 1st quarter valued at approximately $226,000. Wealthedge Investment Advisors LLC purchased a new position in shares of Afya during the 1st quarter valued at $230,000. R Squared Ltd purchased a new position in shares of Afya during the 2nd quarter valued at $264,000. Goldman Sachs Group Inc. increased its stake in shares of Afya by 167.3% in the first quarter. Goldman Sachs Group Inc. now owns 45,093 shares of the company’s stock worth $809,000 after acquiring an additional 28,226 shares during the last quarter. Finally, Campbell & CO Investment Adviser LLC raised its holdings in shares of Afya by 31.5% during the second quarter. Campbell & CO Investment Adviser LLC now owns 51,340 shares of the company’s stock worth $917,000 after acquiring an additional 12,286 shares in the last quarter. 88.02% of the stock is owned by hedge funds and other institutional investors.

Afya Stock Down 0.6%

AFYA opened at $14.79 on Tuesday. The firm has a market cap of $1.39 billion, a P/E ratio of 10.64, a price-to-earnings-growth ratio of 0.45 and a beta of 0.57. The company has a debt-to-equity ratio of 0.21, a quick ratio of 0.98 and a current ratio of 0.98. The business has a 50 day moving average price of $14.95 and a 200 day moving average price of $15.94. Afya Limited has a twelve month low of $13.47 and a twelve month high of $19.90.

Analyst Ratings Changes

A number of brokerages have commented on AFYA. Wall Street Zen upgraded Afya from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 15th. JPMorgan Chase & Co. raised Afya from a “neutral” rating to an “overweight” rating and boosted their price target for the company from $23.50 to $24.50 in a research note on Monday, September 8th. Morgan Stanley set a $17.50 price objective on Afya and gave the stock an “overweight” rating in a report on Wednesday, August 6th. Weiss Ratings reiterated a “hold (c)” rating on shares of Afya in a research note on Wednesday, October 8th. Finally, Citigroup upgraded shares of Afya from a “sell” rating to a “neutral” rating and dropped their price target for the stock from $16.00 to $14.00 in a research note on Tuesday, July 29th. Three research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $18.20.

Afya Company Profile

Afya Limited, through its subsidiaries, operates as a medical education group in Brazil. The company operates through three segments: Undergrad, Continuing Education, and Digital Services. It offers educational products and services, including medical schools, medical residency preparatory courses, graduate courses, and other programs to lifelong medical learners enrolled across its distribution network, as well as to third-party medical schools.